Translating Imaging Into 3D Printed Cardiovascular Phantoms: A Systematic Review of Applications, Technologies, and Validation
- PMID: 36337920
- PMCID: PMC9626905
- DOI: 10.1016/j.jacbts.2022.01.002
Translating Imaging Into 3D Printed Cardiovascular Phantoms: A Systematic Review of Applications, Technologies, and Validation
Abstract
Translation of imaging into 3-dimensional (3D) printed patient-specific phantoms (3DPSPs) can help visualize complex cardiovascular anatomy and enable tailoring of therapy. The aim of this paper is to review the entire process of phantom production, including imaging, materials, 3D printing technologies, and the validation of 3DPSPs. A systematic review of published research was conducted using Embase and MEDLINE, including studies that investigated 3DPSPs in cardiovascular medicine. Among 2,534 screened papers, 212 fulfilled inclusion criteria and described 3DPSPs as a valuable adjunct for planning and guiding interventions (n = 108 [51%]), simulation of physiological or pathological conditions (n = 19 [9%]), teaching of health care professionals (n = 23 [11%]), patient education (n = 3 [1.4%]), outcome prediction (n = 6 [2.8%]), or other purposes (n = 53 [25%]). The most common imaging modalities to enable 3D printing were cardiac computed tomography (n = 131 [61.8%]) and cardiac magnetic resonance (n = 26 [12.3%]). The printing process was conducted mostly by material jetting (n = 54 [25.5%]) or stereolithography (n = 43 [20.3%]). The 10 largest studies that evaluated the geometric accuracy of 3DPSPs described a mean bias <±1 mm; however, the validation process was very heterogeneous among the studies. Three-dimensional printed patient-specific phantoms are highly accurate, used for teaching, and applied to guide cardiovascular therapy. Systematic comparison of imaging and printing modalities following a standardized validation process is warranted to allow conclusions on the optimal production process of 3DPSPs in the field of cardiovascular medicine.
Keywords: 3D printing; 3D, 3-dimensional; 3DPSP, 3-dimensional printed patient-specific phantom; AM, additive manufacturing; CCT, cardiac computed tomography; CMR, cardiac magnetic resonance; DICOM, Digital Imaging and Communications in Medicine; FDM, fused deposition modeling; PBF, powder bed fusion; SLA, stereolithography; TEE, transesophageal echocardiography; VP, voxel printing; additive manufacturing; cardiovascular disease; patient-specific phantoms; personalized medicine; silicone casting; voxel printing.
© 2022 The Authors.
Conflict of interest statement
Dr Nguyen has received funding from the National Institutes of Health and the American Heart Association. Dr Windecker has received research and educational grants to the institution from Abbott, Amgen, AstraZeneca, Bristol Myers Squibb, Bayer, Biotronik, Boston Scientific, Cardinal Health, Cardiovalve, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, Infraredx, Johnson and Johnson, Medicure, Medtronic, Novartis, Polares, OrPha Suisse, Pfizer, Regeneron, Sanofi, Sinomed, Terumo, and V-Wave; serves as an unpaid advisory board member and/or unpaid member of the steering or executive groups of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, Terumo, V-Wave, and Xeltis (but has not received personal payments from pharmaceutical companies or device manufacturers); and is a member of the steering or executive committee groups of several investigator-initiated trials that receive funding from industry, without impact on his personal remuneration. Dr Praz is a consultant for Edwards Lifesciences. Dr Haeberlin has received travel and educational grants from Medtronic and Philips/Spectranetics; is a consultant and advisor for DiNAQOR and Biotronik; and is a cofounder and head of Act-Inno, a device testing company. Dr Pilgrim has received research grants to the institution from Boston Scientific, Edwards Lifesciences, and Biotronik; has received speaker fees from Boston Scientific and Biotronik; is a proctor for Medtronic; and has received reimbursement for travel expenses from Medira. Dr Gräni has received research funding from the Swiss National Science Foundation and Innosuisse, outside the submitted work; and has received travel fees from Amgen and Bayer, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures
References
-
- Sun L., Fukuda T., Tokuhara T., Yabuki N. Differences in spatial understanding between physical and virtual models. Front Architectural Res. 2014;3:28–35.
-
- Giannopoulos A.A., Mitsouras D., Yoo S.J., Liu P.P., Chatzizisis Y.S., Rybicki F.J. Applications of 3D printing in cardiovascular diseases. Nat Rev Cardiol. 2016;13:701–718. - PubMed
-
- Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–e34. - PubMed
